Rating: HOLD
HOLD (5-tier) · mature cash generator · conviction: medium
| Metric | Value |
|---|---|
| Current Price | $99 |
| Triangulated Fair Value | $82 (-17% vs spot · triangulated FV) |
| 12-mo Scenario PWEV | $97 (-2% vs spot · 12m PWEV) |
| Forward P/E | 26.2x |
| Market Cap | $24B |
| 52-Week Range | $81–$106 |
EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).
Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-26. Each chart below sits with the part of the thesis it evidences.
General research for a skeptical institutional reader. Not personalised investment advice; no position sizing or trade instructions. Figures as of the analysis date; verify before acting.
Investment Committee Summary
| Rating | HOLD · HOLD (5-tier) |
| Classification · conviction | mature cash generator · medium |
| Triangulated fair value | $82 (-17% vs spot · triangulated FV) |
| 12-mo scenario PWEV | $97 (-2% vs spot · 12m PWEV) |
| Next catalyst | 2026-07-31 — Quarterly earnings |
| Primary thesis-break | organic revenue growth (YoY) < 0.015 (2 consecutive prints) |
📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.
Rating Bridge
Rating = HOLD because:
- Probability-weighted scenario value implies -2% vs spot
- Monte Carlo median implies -12% vs spot
- DCF fair value implies -23% vs spot
- Bear case (Structural — Private-Label / Brand Erosion) downside is -55% vs spot
- Net: reward/risk of 0.3× is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.
Investment Thesis
At $96.88 (26 June 2026) CHD trades on 25.7x forward earnings against a household-staples peer median of 15.1x. The market is paying a premium for roughly 4% pricing-led organic growth and a 17.8% operating margin, and treating both as durable. The engine is less generous. The DCF anchors fair value at $78.68 per share ($73.94 on a Gordon terminal), peer-multiple triangulation implies $57 to $58, and the Monte Carlo median sits at $87.68 with 40.7% of simulated paths above spot. The probability-weighted target of $98.02 is held up almost entirely by the 34% base case and the 28% of weight in the two upside scenarios, where the premium sits in the multiple rather than in earnings. The rating is HOLD because the 1.2% gap between target and spot is inside noise. The most damaging risk is structural private-label substitution: at 20% probability that scenario carries a $45.48 target, below the $80.53 52-week low, and no defensive multiple survives it.
The dashboard below is the whole argument on one page: spot ($99) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
The bear mechanism is substitution, not recession. CHD's portfolio is concentrated in mid-priced household staples — laundry, litter, personal care — where private label is closest in quality and retailers control the shelf. If trade-down persists beyond one cycle, retailers reallocate facings to own-brand, promotional intensity rises, and pricing power inverts: volume must be bought back with discount. Revenue declines around 4% while operating margin compresses toward 12.5% as fixed costs deleverage and the value positioning of the core Arm & Hammer franchise caps price recovery. Earnings power near $2.47 per share meets a de-rated 18x multiple — a stock in the mid-40s. The vitamins franchise has already shown how quickly a CHD category can impair; 25.7x forward earnings concedes none of that fragility.
Key Debate
P/E Multiple explains 54% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q1): management +0.53 vs analyst floor +0.00 → delta +0.53 (n=22 mgmt / 15 Q&A; 79th pctile across the S&P book, z +0.8).
Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q1 | +0.53 | +0.00 | +0.53 |
| 2025Q4 | +0.75 | — | — |
| 2025Q3 | +0.39 | +0.23 | +0.16 |
| 2025Q2 | +0.52 | +0.33 | +0.19 |
News (last 365d, 905 articles): avg ticker sentiment +0.15 (bullish 16% / bearish 2%)
Scenario Analysis
The tree runs from a structural 'Structural — Private-Label / Brand Erosion' downside ($44) to a 'Bull — Defensive Re-Rate' bull case ($156); the probability-weighted blend (PWEV $97) is -2% versus spot.
| Scenario | Probability | Target | Return vs spot |
|---|---|---|---|
| Structural — Private-Label / Brand Erosion | 20% | $44 | -55% |
| Consumer / Input Recession | 18% | $80 | -19% |
| Base — Pricing-Led Organic Growth | 34% | $103 | +4% |
| Growth — Premium Innovation + EM | 20% | $129 | +30% |
| Bull — Defensive Re-Rate | 8% | $156 | +57% |
| Probability-Weighted (PWEV) | — | $97 | -2% |
Scenario rationale — what each probability buys (the driver path behind every target):
- Structural — Private-Label / Brand Erosion (20%, $44). Structural impairment — private-label / brand erosion: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 45.48; probability: 0.2.
- Consumer / Input Recession (18%, $80). Cyclical downturn — branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail) weakens for 1–2 years before normalising. Drivers — implied_target: 80.81; probability: 0.18.
- Base — Pricing-Led Organic Growth (34%, $103). Mid-cycle — normalised branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail); disciplined capital allocation; steady returns. Drivers — implied_target: 104.56; probability: 0.34.
- Growth — Premium Innovation + EM (20%, $129). Upside — premium innovation + emerging markets lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 132.02; probability: 0.2.
- Bull — Defensive Re-Rate (8%, $156). Upside tail — sustained tight conditions or a structural re-rate on premium innovation + emerging markets. Drivers — implied_target: 155.28; probability: 0.08.
Valuation Triangulation
Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.
| Method | Basis | Fair Value | vs Spot |
|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $87 | -12% |
| Peer P/E re-rate | multiple | $57 | -42% |
| Peer EV/Revenue re-rate | multiple | $58 | -41% |
| Scenario PWEV | multiple | $97 | -2% |
| DCF (5-year + terminal) | cash flow + terminal × | $76 | -23% |
| Triangulated (weighted) | — | $82 | -17% |
Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.
Rating vs blend — the key debate. The rating tracks the multiple-discipline fair value (Monte Carlo $87 + scenario PWEV $97, ≈ spot); the weighted blend $82 (-17%) sits below it because the cash-flow DCF ($76) is materially more conservative than the market multiple. Whether the current multiple is justified is the central question for this name — and the principal downside risk to the rating.
Monte Carlo — the distribution, not a point
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $87 and 38% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (54% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.
DCF — the cash-flow anchor
Independent of the market multiple: a 5-year path, WACC 7.5%, 22x terminal FCF multiple → $76. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.
Peer benchmarking — relative value
Against the peer cohort, re-rating to the peer-median forward multiple (P/E 15.13x) implies $57. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.
Across all anchors the spread is 52% of the median — wide (genuine disagreement — the blend carries low valuation confidence).
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Op margin | EBIT | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|---|
| Household & Personal Care | $6.2B | 100% | 4% | 18% | $1.1B | 26x | 3% | ESTIMATE |
| EBIT = segment revenue × operating margin (segment EBITDA not shown — per-segment D&A is not separately disclosed). |
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail) |
| net_debt_or_cash_b | -1.87 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.03 |
| div_yield | 0.0121 |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | private-label / brand erosion |
| upside | premium innovation + emerging markets |
Industry Context — Consumer Staples — Household
This name sits in the Consumer Staples — Household as a household_personal. branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail) Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.
Value chain: PG (household_personal) · CL (household_personal) · KVUE (household_personal) · KMB (household_personal) · EL (household_personal) · CHD (household_personal) · CLX (household_personal)
| Shared state | Capex path | House view | This name implies |
|---|---|---|---|
| Structural — Private-Label / Brand Erosion | 38% | 38% | |
| Mid-Cycle — Pricing-Led Organic Growth | 34% | 34% | |
| Upside — Premium Innovation / EM | 28% | 28% |
Mapping note: name-level 'Structural — Private-Label / Brand Erosion' (20%) + 'Consumer / Input Recession' (18%) map to cluster Structural — Private-Label / Brand Erosion (38%); name-level 'Growth — Premium Innovation + EM' (20%) + 'Bull — Defensive Re-Rate' (8%) map to cluster Upside — Premium Innovation / EM (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.
On the cluster's key downside — Structural — Private-Label / Brand Erosion () — this name implies 38% vs the cluster house view of 38% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.
Structure: Shared State — The staples_household cycle is the shared macro driver. Driver — branded HPC pricing power + organic volume + input costs Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).
Model Appendix
DCF — line items
| Year | Revenue | Op income | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $6B | $1B | $0B | $0B | $1B | $1B |
| FY+2 | $7B | $1B | $0B | $0B | $1B | $1B |
| FY+3 | $7B | $1B | $0B | $0B | $1B | $1B |
| FY+4 | $7B | $1B | $0B | $0B | $1B | $1B |
| FY+5 | $7B | $1B | $0B | $0B | $1B | $1B |
| Terminal | — | — | — | — | $1B × 22x | $16B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 3% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 7.5% · Σ PV(FCF) $4B + PV(terminal) $16B = EV $20B; + net cash → equity $18B ÷ diluted shares 0.24B = $76/share (exit-multiple terminal).
- Gordon (perpetuity-growth) terminal at 2.5% → $71/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
- Incremental ROIC on the forecast capex ≈ 20% vs WACC 8% → above WACC — the build is value-creative.
Peer set
| Peer | EV/Rev | Fwd P/E | Growth | Op margin |
|---|---|---|---|---|
| CL | 3.823x | 23.58x | 4% | 21% |
| KMB | 2.535x | 14.22x | 4% | 20% |
| CLX | 2.192x | 15.13x | 4% | 17% |
| Median | 2.535x | 15.13x | — | — |
Peer-median fwd P/E → $57; EV/Rev → $58.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| DCF | $76 | 41% | $31 |
| Scenario PWEV | $97 | 29% | $28 |
| Monte Carlo median | $87 | 18% | $15 |
| Peer P/E | $57 | 12% | $7 |
| Triangulated | — | 100% | $82 |
Sensitivity
DCF/share — WACC × terminal multiple
| WACC \ Term× | 15.4x | 18.7x | 22.0x | 25.3x | 28.6x |
|---|---|---|---|---|---|
| 6% | $61 | $73 | $84 | $95 | $106 |
| 6% | $59 | $69 | $80 | $90 | $101 |
| 8% | $56 | $66 | $76 | $86 | $96 |
| 8% | $53 | $63 | $73 | $82 | $92 |
| 10% | $51 | $60 | $69 | $78 | $88 |
DCF/share — revenue CAGR Δ × op-margin Δ
| CAGRΔ \ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $53 | $59 | $65 | $71 | $77 |
| -1.5pp | $57 | $64 | $70 | $77 | $83 |
| +0.0pp | $62 | $69 | $76 | $83 | $90 |
| +1.5pp | $67 | $75 | $82 | $89 | $97 |
| +3.0pp | $72 | $80 | $88 | $96 | $104 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Op margin ±3pp | $62 | $90 | $28 |
| Revenue CAGR ±3pp | $65 | $88 | $23 |
| Terminal × ±15% | $66 | $86 | $20 |
| WACC ±1pp | $73 | $80 | $7 |
| Capex intensity ±15% | $73 | $79 | $5 |
Company lever — SoP/share vs Household & Personal Care multiple (AI re-rating) (base 26x)
| Multiple | 18.2x | 22.1x | 26.0x | 29.9x | 33.8x |
|---|---|---|---|---|---|
| SoP/share | $468 | $570 | $672 | $774 | $876 |
Consensus & Market Expectations
| Reference | Value |
|---|---|
| Street target (mean) | $103 (+4% vs spot · street) |
| House target | $98 (-4.4% vs street) |
| Sell-side coverage | 21 analysts (SB 2 / B 8 / H 9 / S 0 / SS 2; net score 0.19) |
| Consensus FY EPS | $4.09; house below (-7.8%) |
| Consensus FY revenue | $6.5B; house in-line (+0.4%) |
_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.
Balance Sheet & Liquidity
| Metric | Value |
|---|---|
| Net debt | $1.8B — modestly levered |
| Net debt / EBITDA | 1.29x |
| Interest coverage (EBIT / interest) | 11.1x |
| Current ratio | 1.07x |
| Cash & ST investments | $0.4B |
Balance-sheet data as of 2025-12-31 (Alpha Vantage).
Capital Allocation
| Metric | Value |
|---|---|
| Free cash flow | $1.1B |
| Buybacks / dividends | $0.9B / $0.3B |
| Total shareholder yield | 5.0% |
| Payout as % of FCF | 108.6% |
| Reinvestment (capex / OCF) | 10.0% |
| SBC as % of FCF | 5.3% |
| Allocation stance | returning more than FCF (balance-sheet funded) |
Free-Cash-Flow Quality
| Metric | Value |
|---|---|
| FCF margin | 17.6% |
| FCF conversion (FCF / net income) | 148.3% |
| FCF yield | 4.6% |
| Capex intensity (capex / revenue) | 2.0% |
| FCF − SBC (diagnostic) | $1.0B |
| Capex split (maint / growth) | 70% / 30% — Capital-light HPC manufacturer; capex ~2-3% of revenue is mostly maintenance and automation, with a growth slice for capacity behind newer brands and vitamins |
Accounting quality: SBC 0.9% of revenue; cash conversion (OCF/NI) 165% — cash-backed.
Catalyst Calendar
- 2026-07-31 (~23d) — Quarterly earnings — est. EPS $0.90 (AV EARNINGS_CALENDAR)
- 2026-10-15 (~99d) — Bolt-on acquisition close / capital-deployment update (authored)
- 2027-01-28 (~204d) — FY2026 results + FY2027 organic-growth and margin guidance (authored)
- 2027-02-15 (~222d) — Long-range algorithm / investor update (authored)
Forecast Track Record
- EPS surprise: beat 87.5% of the last 8 quarters; average surprise +6.6%.
Competitive Moat
Narrow moat. A narrow moat built on a handful of #1/#2 category brands (ARM & HAMMER, OxiClean, vitamins) plus a value-tier hedge justifies a modest premium to the staples median, but not the ~25x forward multiple embedded today; if private label keeps taking mid-tier share (the falsifiable test), the terminal multiple should compress toward the ~16x household-staples median rather than hold near 20x.
Moat sources:
- FACT: portfolio of 'power brands' with roughly 40% of profit from a concentrated set of #1/#2 share categories (10-K category disclosure)
- FACT: dual value/premium positioning (ARM & HAMMER value tier) that captures trade-down as well as trade-up
- INFERENCE: shelf-space and retailer-relationship scale at Walmart/Amazon, though below CL/PG in bargaining power
- ABSENCE: no structural switching costs or network effects; brand equity is the sole moat source and is erodible by private label
Regulatory & Legal Risk
| Issue | Probability | Valuation sensitivity | Horizon |
|---|---|---|---|
| FTC/state scrutiny of vitamins & supplements (VMS) health claims and 'clean'/natural labeling | medium (~30%) | low - confined to the VMS sub-portfolio, ~3-5% of FV | 12-24m |
| Ingredient/packaging and recyclability mandates raising COGS | medium (~35%) | low - margin drag absorbable via pricing, <3% of FV | 12-24m |
Probabilities and sensitivities are analyst estimates, not market-implied.
Scenario Macro & Key Risks
| Scenario | Macro assumption | Key risk |
|---|---|---|
| Structural — Private-Label / Brand Erosion | Persistent consumer trade-down and retailer private-label expansion (Walmart/Amazon own-brand push) compress branded HPC volume and pricing power together | Brand equity proves rentable rather than owned; volume AND multiple de-rate together toward private-label economics |
| Consumer / Input Recession | A consumer-spending recession with elevated commodity/logistics input costs squeezes both the top line and gross margin for 1-2 years | Pricing exhaustion; CHD cannot raise price further without ceding volume, so margin absorbs the input shock |
| Base — Pricing-Led Organic Growth | Normalised low-single-digit category volume with ~4% pricing-led organic growth and stable ~18% operating margin | Volume stays negative and 'organic growth' is entirely price, which is not repeatable indefinitely |
| Growth — Premium Innovation + EM | Successful premium innovation (VMS, specialty laundry) and international/EM expansion lift both volume and mix above the base | Innovation cadence and acquisitions fail to scale internationally where CHD lacks distribution density |
| Bull — Defensive Re-Rate | A risk-off macro regime drives a flight to defensive staples, expanding the multiple even without fundamental improvement | Re-rate is macro-driven and reverses as soon as risk appetite returns; not a durable source of value |
What the Market Is Pricing In
At the current price, the market pays 24.2× forward EPS, vs the house DCF terminal 22.0×, and a peer median 15.13×. The house DCF sits 23% below spot, so the market is pricing in more than the house case — roughly 2.3pp of revenue CAGR.
Variant perception: the house view is below-consensus, and the thesis is primarily event-driven.
| Metric | Consensus | House | Importance |
|---|---|---|---|
| Revenue | 6.5 | 6.5 | High |
| EPS | 4.1 | 3.8 | Medium |
| Target price | 102.5 | 98.0 | Medium |
Peer Quality & Weighting
| Peer | Fwd P/E | Growth | Op margin | Quality | Weight cap |
|---|---|---|---|---|---|
| CL | 23.58× | 4% | 21% | direct | 100% |
| KMB | 14.22× | 4% | 20% | segment | 50% |
| CLX | 15.13× | 4% | 17% | segment | 50% |
Quality-weighted forward P/E: 19.1× (simple median 15.13×). Direct peers count 100%, segment 50%, broad 25%.
Historical-range cross-check: 52-week range $81–$106, centre $92 (-7% vs spot); spot sits at the 73th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.
Risk / Reward & Margin of Safety
| Metric | Value |
|---|---|
| Upside to triangulated FV | $82 (-17% vs spot · triangulated FV) |
| Downside to bear case (Structural — Private-Label / Brand Erosion) | $44 (-55% vs spot · bear scenario) |
| Reward/risk ratio | 0.3× |
| Margin of safety (FV vs spot) | -21% |
| P(price > spot) — Monte Carlo | 38% |
Reward/risk compares triangulated upside against the probability-weighted bear target, not the extreme tail. Bull case (Bull — Defensive Re-Rate): $156.
Assumption Register
| Assumption | Value | Used in | Source |
|---|---|---|---|
| WACC | 7.5% | DCF discount rate | estimate (CAPM) |
| Terminal multiple | 22× | DCF exit value | estimate (peer-anchored) |
| Terminal growth | 2.5% | DCF Gordon terminal | estimate |
| SBC dilution | 0.0%/yr | PWEV, MC, DCF (charged once) | estimate (from SBC/rev) |
| EPS basis | consensus forward EPS (broker-adjusted, non-GAAP) | all forward P/E & scenario multiples | definition |
Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (28.0); Revenue CAGR ±3pp (23.0); Terminal × ±15% (20.0); WACC ±1pp (7.0); Capex intensity ±15% (5.0).
Inputs, Sources & Confidence
Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)
| Input | Value | Type | Source | Confidence | Used in |
|---|---|---|---|---|---|
| Revenue TTM | $6.2B | reported fact | 10-K/10-Q via AV | High | Forecast base, EV/Rev |
| FY+1 guided revenue | $6.5B | company guidance | Company guidance | Medium | Forecast, SoP |
| Consensus FY EPS | $4.0897 | consensus estimate | Sell-side consensus via AV | Medium | Variant perception |
| Diluted shares | 0.238B | reported fact | 10-K via AV | High | Market cap, per-share |
| Net debt / cash | $1.796B | reported fact | Balance sheet via AV | High | EV, DCF equity bridge |
| WACC | 7.5% | house estimate | CAPM (beta/rf) | Medium | DCF discount rate |
| Terminal multiple | 22× | house estimate | Peer/historical range | Medium | DCF exit value |
| Terminal growth | 2.5% | house estimate | Long-run GDP+ | Medium | DCF Gordon terminal |
Source Log
| Source | Type | Date | Used for | Reference |
|---|---|---|---|---|
| Alpha Vantage — GLOBAL_QUOTE / OVERVIEW | market data | 2026-07-08 | Price, market cap, EV, 52-week range, forward P/E | Alpha Vantage 2026-06-26 |
| Company income statement (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-07-08 | Revenue, gross/operating margin, EBIT, interest expense | INCOME_STATEMENT / latest annual |
| Company balance sheet (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-07-08 | Cash, debt, net debt, leases, equity, coverage | BALANCE_SHEET / latest annual |
| Company cash-flow statement (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-07-08 | Operating cash flow, capex, FCF, buybacks, dividends, SBC | CASH_FLOW / latest annual |
| Company earnings releases via Alpha Vantage | reported fact | 2026-07-08 | Reported EPS, surprise history | EARNINGS / quarterly |
| Sell-side consensus via Alpha Vantage | consensus estimate | 2026-07-08 | Forward revenue/EPS consensus, analyst count | EARNINGS_ESTIMATES |
| Earnings calendar via Alpha Vantage | market data | 2026-07-08 | Next earnings date, catalyst timing | EARNINGS_CALENDAR |
| Company guidance | company guidance | 2026-07-08 | FY guided revenue / non-GAAP EPS basis | company guidance / earnings call |
| MCH segment model (from filings & disclosures) | house estimate | 2026-07-08 | Segment revenue, margins, multiples, AI decomposition | company_context (authored, tagged) |
| MCH qualitative analysis | inference | 2026-07-08 | Moat, regulatory risk, scenario macro, catalysts | company_context enrichment (authored) |
| MCH investment thesis & falsification triggers | house estimate | 2026-07-08 | Thesis, anti-thesis, thesis-break signals | authored §5.3 |
Citation coverage: 13/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.
Load-Bearing Assumptions
DCF: WACC 8%, terminal multiple 22×, FY+5 revenue $7B. Triangulation leans 41% on DCF, 29% on PWEV.
Reasons the Thesis Could Fail (Falsifiable)
Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:
- organic revenue growth (YoY) < 0.015 (2 consecutive prints → staples_household). Midpoint of the base scenario growth driver (0.04) and the Consumer / Input Recession driver (-0.01). Two prints below 1.5% organic means pricing-led growth has stalled and the base case is no longer the modal path.
- operating margin (quarterly, non-GAAP) < 0.165 (2 consecutive prints → staples_household). Midpoint of the base margin (0.178) and the recession margin (0.155). Sustained prints below 16.5% indicate input-cost pass-through has broken or promotional intensity is rising, shifting weight toward the bear scenarios.
- organic volume growth (YoY) < 0.0 (2 consecutive prints → staples_household). Growth that is entirely price with negative volume is the observable signature of private-label substitution — the mechanism of the structural scenario. Two consecutive negative volume prints move probability from Base to Structural.
- FY organic sales growth guidance < 0.02 (single event → staples_household). A full-year guide below 2% organic is management conceding the pricing-led algorithm, roughly halving the base scenario growth driver. Discrete, observable at the print on which it is issued.
- brand impairment or intangible write-down ($B) > 0.1 (single event → staples_household). A material write-down on an acquired brand (the vitamins franchise is the precedent) is direct evidence that a category has structurally impaired, validating the brand-erosion mechanism rather than a cyclical soft patch.
Fact / Inference / Speculation
- FACT: Spot $99; 52-week range $81–$106; engine rating HOLD; base-case target $98 (-1%). (source: Alpha Vantage 2026-06-26, 8 July 2026)
- INFERENCE: Triangulated FV $82 (-17% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
- SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.
Recommendation: HOLD
Balanced: triangulated fair value $82 (-17% vs spot); the outcome hinges on P/E Multiple. The debate is P/E Multiple — fundamentally a multiple/regime call.
Disclosures & Limitations
This report is for informational and research purposes only. It is not personalised investment advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.
- No suitability assessment has been performed for any individual.
- Market data may be delayed or inaccurate; figures are as of the analysis date.
- Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
- Forecasts are uncertain; past performance is not indicative of future returns.
- The author or publisher may hold positions in securities mentioned.
- Users should verify information against primary sources (company filings) before acting.
- Investing involves risk of loss; there is no guarantee any target price is achieved.
- Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.